CAS 191732 -72-6 Lenalidomide

China CAS 191732-72-6 Lenalidomide, Find details about China Lenalidomide, 191732-72-6 from CAS 191732-72-6 Lenalidomide

Basic Info.

Model NO.

TY-02ALI

CAS No.

191732-72-6

Appearance

White Powder

Einecs

616-396-9

Assay

99%

Shelf

2 Years

Trademark

tongyon

Transport Package

25kg/Drum 1kg, 10kg, 100kg, 200kg

Specification

25kg/drum

Origin

China

Model NO.

TY-02ALI

CAS No.

191732-72-6

Appearance

White Powder

Einecs

616-396-9

Assay

99%

Shelf

2 Years

Trademark

tongyon

Transport Package

25kg/Drum 1kg, 10kg, 100kg, 200kg

Specification

25kg/drum

Origin

China

Product Desciption

Product name	Lenalidomide
CAS	191732-72-6
Appearance	white powder
Assay	99%
Storage	Cool and Protect from light

Product Name:Lenalidomide
CAS:191732-72-6
MF:C13H13N3O3
MW:259.26062
EINECS:691-297-1
Mol File:191732-72-6.mol
Melting point:269-271°C
Boiling point:614.0±55.0 °C(Predicted)
Density 1.460±0.06 g/cm3(Predicted)
storage temp. -20°C Freezer
pka10.75±0.40(Predicted)

CAS 191732-72-6 Lenalidomide

Description
Lenalidomide is a kind of antitumor drugs that developed by American biological pharmaceutical companies. Its chemical structure is similar with thalidomide. It has many functions such as anti-tumor, immune regulation and anti-angiogenesis. It can inhibit the secretion of inflammatory cytokines, and increase the secretion of peripheral blood mononuclear anti-inflammatory cytokines. Vitro tests show that lenalidomide can inhibit the hyperplasia of some cell lines such as namalwa cell. It can inhibit the growth of patients' multiple myeloma cells and MM1S cell. In addition, lenalidomide also can inhibit the expression of oxidase-2 (COX-2), but it has no effect on COX-1. Two multicenter randomized double-blind placebo-controlled clinical studies evaluate the safety and curative effect of lenalidomide that is used for multiple myeloma. The primary efficacy end point of the studies is time to progression (TTP). The interim analysis shows that TTP of the combination group is significantly superior to dexamethasones group. Recent clinical research results show that lenalidomide not only has curative effect on treating MDS and MM, but also on treating myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized amyloidosis and systemic bone marrow fibrosis disease with marrow unripe.

GuangZhou TongYi biochemistry technology Co., Ltd is a company specializing in active pharmaceutical ingredient
(API), biology, plant extracts, chemical raw materials, fine chemicals, pharmaceutical intermediates, cosmetics raw
material. Our company has always adhered to the company philosophy of integrity, professionalism, quality first, and
customer service. With the efforts of all the company's employees, it has established long-term
and stable cooperative relations with many domestic and foreign customers, and won the unanimous trust of domestic
and foreign customers. With good comments, our company have made great progress.

Our company takes pioneering and innovative, high-quality and efficient as the code of conduct, and strives to provide
customers with efficient services,
high-quality products, and reasonable prices. We have established a customer demand-oriented, flexible, diverse and customizable service according to the different needs of different customers. Mode, and ultimately achieve the goal of
win-win.

Our company focuses on the future and the world, and will continue to devote itself to technological progress and the
development of new products in the future, hoping to work hand in hand with new and old friends at home and abroad
to create a better future.

CAS 191732-72-6 Lenalidomide